Drug Trial Radar · NCT07226349
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Dec 11, 2025
Primary completion
Nov 1, 2028
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Nov 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75098 alone and in combination with BGB-43395 and fulvestrant in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
BG-75098Drug
Administered orally.
BGB-43395Drug
Administered orally.
FulvestrantDrug
Administered by intramuscular injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1a: Number of Participants with Adverse Events (AEs)Time frame: From first dose to 30 days after last dose, up to approximately 12 months
- Phase 1a: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-75098Time frame: Up to approximately 2 years
- Phase 1a: Recommended Dose(s) for Expansion (RDFE[s]) of BG-75098 as Monotherapy and in Combination with BGB-43395 and FulvestrantTime frame: Up to approximately 2 years
- Phase 1b: Objective Response Rate (ORR) as Assessed by the InvestigatorTime frame: Up to approximately 2 years
Locations
23 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham Hospital
Birmingham, Alabama · Recruiting
City of Hope National Medical Center
Duarte, California · Recruiting
Yale Cancer Center
New Haven, Connecticut · Recruiting
Sidney Kimmel Comprehensive Cancer At Johns Hopkins
Baltimore, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
The University of Texas Md Anderson Cancer Center
Houston, Texas · Recruiting
Next Oncology Houston
Houston, Texas · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australia · Recruiting
Genesiscare St Leonards
St Leonards, New South Wales, Australia · Recruiting
Icon Cancer Centre Wesley
Auchenflower, Queensland, Australia · Recruiting
Cabrini Hospital Malvern
Malvern, Victoria, Australia · Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
One Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
Guangzhou, Guangdong, China · Recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technologyjinyinhu Branch
Wuhan, Hubei, China · Recruiting
Jiangsu Province Hospital Longjiang Branch
Nanjing, Jiangsu, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Weifang Peoples Hospital
Weifang, Shandong, China · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.